PLK1 and head and neck squamous cell carcinoma: BI-2536, primarily targeting the ATP-binding domain of Polo-Like Kinase-1 (PLK1),34 has been shown to reduce clonogenic, invasive, and migratory abilities of HNSCC cells, particularly when combined with Erastin (a ferroptosis inducer).35